Experts discuss optimizing NALIRIFOX treatment for metastatic pancreatic cancer, highlighting flexible dosing and early adverse event recognition for better patient outcomes.
Combination Chemotherapy in Patients With Pancreatic Cancer
Maen Abdelrahim, MD, PhD, discusses how to manage the dose of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma.
During a live event, Kashif Ali, MD, discussed outcomes from the NAPOLI 3 trial in terms of efficacy, tolerability, and dose modification.
During a live event, Kashif Ali, MD, reviewed the efficacy and safety of the NAPOLI 1 trial in patients with pancreatic cancer.